Response to Gungor et al. Regarding Morishita et al., “Association of Quinolone Exposure in the First Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan”
Pharmacoepidemiology and Drug Safety · 2026-11 · 35 (11)
DOI: 10.1002/pds.70524 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 08.11.2026. Verfasst von Kei Morishita und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Miyagi, Japan. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Key Points This response provides additional agent‐specific exposure and outcome data for all quinolone agents included in our original study in response to the comment by Gungor et al. Moxifloxacin, garenoxacin, ofloxacin, tosufloxacin, and norfloxacin exhibited crude prevalence of MCMs that were numerically higher than the prevalence for all quinolone agents combined. We added exact 95% CIs to indicate the precision of these estimates. Reliable comparisons between individual quinolone agents were not possible because the analyses were descriptive and unadjusted, and several estimates were based on small numbers of exposures or outcomes. Therefore, these findings should be interpreted as hypothesis‐generating.
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Miyagi, Japan.
- Department of Molecular Epidemiology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
- Drug Informatics, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan.
- Division of Preventive Medicine and Epidemiology, Tohoku University Tohoku Medical Megabank Organization, Sendai, Miyagi, Japan.
ORCID-Profile: Kei Morishita, Takamasa Sakai, Taku Obara
Zitieren
APA
Morishita, K., Sakai, T., & Obara, T. (2026). Response to Gungor et al. Regarding Morishita et al., “Association of Quinolone Exposure in the First Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan”. Pharmacoepidemiology and Drug Safety, 35(11). https://doi.org/10.1002/pds.70524
Vancouver
Morishita K, Sakai T, Obara T. Response to Gungor et al. Regarding Morishita et al., “Association of Quinolone Exposure in the First Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan”. Pharmacoepidemiology and Drug Safety. 2026;35(11). doi:10.1002/pds.70524
BibTeX
@article{Morishita2026,
author = {Morishita, Kei and Sakai, Takamasa and Obara, Taku},
title = {Response to Gungor et al. Regarding Morishita et al., “Association of Quinolone Exposure in the First Trimester of Pregnancy and the Risk of Major Congenital Malformations: A Health Administrative Database Study in Japan”},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
volume = {35},
number = {11},
doi = {10.1002/pds.70524}
}
EUVIMED